List of Excipients in Branded Drug DANTROLENE SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	FD&C YELLOW NO. 6
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	FERRIC OXIDE RED
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	FERRIC OXIDE YELLOW
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	GELATIN
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	LACTOSE MONOHYDRATE
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	MAGNESIUM STEARATE
Endo USA Inc	DANTROLENE SODIUM	dantrolene sodium	49884-362	STARCH, CORN

Generic Drugs Containing DANTROLENE SODIUM

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	CROSCARMELLOSE SODIUM
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	D&C YELLOW NO. 10
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	FD&C GREEN NO. 3
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	FERRIC OXIDE YELLOW
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	GELATIN
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	LACTOSE MONOHYDRATE
Amneal Pharmaceuticals of New York LLC	dantrolene sodium	0115-4411	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in DANTROLENE SODIUM?

# Of NDCs	Excipient
5	BUTYL ALCOHOL
6	CROSCARMELLOSE SODIUM
11	D&C YELLOW NO. 10
5	FD&C BLUE NO. 1
5	FD&C BLUE NO. 2
6	FD&C GREEN NO. 3
5	FD&C RED NO. 40

Excipient Strategy and Commercial Opportunities for Dantrolene Sodium

Last updated: February 25, 2026

What are the key excipient strategies for Dantrolene Sodium?

Dantrolene Sodium is a hydantoin derivative used primarily for treating malignant hyperthermia and certain muscle spasm conditions. Its formulation stability, bioavailability, and shelf life depend significantly on excipient choices.

Standard excipient components

• Sodium hydroxide or hydrochloric acid: Used for pH adjustment.
• Lactose monohydrate: Commonly employed as a filler and diluent.
• Magnesium stearate: A lubricant facilitating tablet manufacturing.
• Microcrystalline cellulose: Binds particles and enhances mechanical strength.
• Preservatives: Methylparaben or benzyl alcohol may be incorporated for parenteral forms to prevent microbial growth.

Formulation considerations

• Solubility: Dantrolene sodium's poor water solubility demands excipients that enhance dissolution, such as surfactants (e.g., sodium lauryl sulfate).
• Stability: Excipients like mannitol or sorbitol may improve stability by reducing moisture interaction.
• Bioavailability: Use of absorption enhancers or complexing agents can improve systemic uptake.

Advanced excipient strategies

• Nanoparticle formulations: Incorporating excipients like PEG (polyethylene glycol) or poloxamers enhances solubility.
• Lipid-based systems: Liposomes or solid lipid nanoparticles utilize excipients such as phosphatidylcholine to improve tissue targeting.
• Controlled release matrices: Polymers like hydroxypropyl methylcellulose enable sustained dosing.

What commercial opportunities exist through excipient innovation?

Patent protection and formulation exclusivity

Innovative excipient combinations or delivery systems can extend product lifecycle beyond the initial patent, offering exclusivity periods of 5-10 years.

Market differentiation

Enhanced formulations that increase bioavailability or stability reduce dosing frequency, which appeals to hospitals and clinics. Parenteral formulations with novel excipients can target critical care settings where rapid action is required.

Expanding indications

Novel delivery systems may enable new therapeutic uses, including chronic neuromuscular conditions or alternative routes of administration like transdermal patches.

Cost considerations

Using excipients derived from cost-effective sources or enabling large-scale manufacturing can reduce production costs, improving margins. Licensing potential arises from proprietary excipient combinations.

Regulatory pathways

Excipients with Generally Recognized as Safe (GRAS) status facilitate faster approval for new formulations. Investment in excipient research aligned with international standards (e.g., ICH Q3A for impurities) supports global market entry.

Strategic partnerships

Collaborations with excipient manufacturers offer opportunities to develop tailored delivery platforms. These collaborations can accelerate product development and commercialization.

What are the risks associated with excipient strategies?

• Regulatory hurdles: New excipients or novel combinations require extensive safety and stability data.
• Formulation complexity: Optimizing excipients to balance stability, bioavailability, and manufacturability poses technical challenges.
• Market acceptance: Convincing clinicians and regulators to adopt new formulations can be slow without robust clinical evidence.

Market outlook and future trends

The global neuromuscular agent market, with Dantrolene Sodium as a major component, is projected to grow at a CAGR of 3.5% through 2028 (Grand View Research, 2022). Innovation in excipient systems, especially lipid-based and nanoparticle formulations, will propel advances in drug delivery.

Key Takeaways

• Excipient choices critically influence Dantrolene Sodium’s stability, bioavailability, and manufacturing.
• Novel excipient systems can extend patent life, facilitate new delivery routes, and enhance product efficacy.
• Regulatory and technical challenges must be addressed when developing innovative formulations.
• Cost-effective excipient sourcing and strategic partnerships support market expansion.
• Future growth hinges on excipient innovations aligned with safety, regulatory, and clinical efficacy standards.

FAQs

1. What excipients are typically used in Dantrolene Sodium tablets?
Lactose monohydrate, microcrystalline cellulose, magnesium stearate, and pH adjusters like sodium hydroxide or hydrochloric acid.

2. How can excipient modifications improve Dantrolene Sodium’s clinical performance?
By enhancing solubility and stability, excipients can improve absorption, reduce dosing frequency, and enable alternative administration routes.

3. Are there innovative excipient technologies in the pipeline for Dantrolene Sodium?
Yes. Lipid-based formulations and nanoparticle systems are under development to improve tissue targeting and bioavailability.

4. What regulatory factors influence excipient development for Dantrolene Sodium?
Use of GRAS status excipients and adherence to ICH guidelines ensure faster approval processes and global market access.

5. Can excipient innovation extend Dantrolene Sodium's patent life?
Yes. Patent protection can be based on novel excipient combinations or delivery platforms that deliver therapeutic advantages.

---

References

1. Grand View Research. (2022). Neuromuscular Disease Market Size, Share & Trends Analysis Report.
2. ICH Q3A(R2). (2009). Impurities in New Drug Substances. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.